Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates
The unprecedented and rapid spread of SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) has motivated the need for a rapidly producible and scalable vaccine. Here, we developed a synthetic soluble SARS-CoV-2 spike (S) DNA-based vaccine candidate, GX-19. In mice, immunization with GX-19 el...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/4/307 |
| _version_ | 1797540220258746368 |
|---|---|
| author | Yong Bok Seo You Suk Suh Ji In Ryu Hwanhee Jang Hanseul Oh Bon-Sang Koo Sang-Hwan Seo Jung Joo Hong Manki Song Sung-Joo Kim Young Chul Sung |
| author_facet | Yong Bok Seo You Suk Suh Ji In Ryu Hwanhee Jang Hanseul Oh Bon-Sang Koo Sang-Hwan Seo Jung Joo Hong Manki Song Sung-Joo Kim Young Chul Sung |
| author_sort | Yong Bok Seo |
| collection | DOAJ |
| description | The unprecedented and rapid spread of SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) has motivated the need for a rapidly producible and scalable vaccine. Here, we developed a synthetic soluble SARS-CoV-2 spike (S) DNA-based vaccine candidate, GX-19. In mice, immunization with GX-19 elicited not only S-specific systemic and pulmonary antibody responses but also Th1-biased T cell responses in a dose-dependent manner. GX-19-vaccinated nonhuman primates seroconverted rapidly and exhibited a detectable neutralizing antibody response as well as multifunctional CD4+ and CD8+ T cell responses. Notably, when the immunized nonhuman primates were challenged at 10 weeks after the last vaccination with GX-19, they had reduced viral loads in contrast to non-vaccinated primates as a control. These findings indicate that GX-19 vaccination provides a durable protective immune response and also support further development of GX-19 as a vaccine candidate for SARS-CoV-2. |
| first_indexed | 2024-03-10T12:57:01Z |
| format | Article |
| id | doaj.art-59e9cddc8f904b8aaa4a7bc45facd25d |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T12:57:01Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-59e9cddc8f904b8aaa4a7bc45facd25d2023-11-21T11:48:56ZengMDPI AGVaccines2076-393X2021-03-019430710.3390/vaccines9040307Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman PrimatesYong Bok Seo0You Suk Suh1Ji In Ryu2Hwanhee Jang3Hanseul Oh4Bon-Sang Koo5Sang-Hwan Seo6Jung Joo Hong7Manki Song8Sung-Joo Kim9Young Chul Sung10Research Institute, SL VaxiGen Inc., Korea Bio Park, Seongnam 13488, KoreaResearch Institute, Genexine Inc., Korea Bio Park, Seongnam 13488, KoreaResearch Institute, SL VaxiGen Inc., Korea Bio Park, Seongnam 13488, KoreaResearch Institute, SL VaxiGen Inc., Korea Bio Park, Seongnam 13488, KoreaNational Primate Research Centre, Korea Research Institute of Bioscience and Biotechnology, Cheongju, Chungcheongbuk 34141, KoreaNational Primate Research Centre, Korea Research Institute of Bioscience and Biotechnology, Cheongju, Chungcheongbuk 34141, KoreaScience Unit, International Vaccine Institute, Seoul 08826, KoreaNational Primate Research Centre, Korea Research Institute of Bioscience and Biotechnology, Cheongju, Chungcheongbuk 34141, KoreaScience Unit, International Vaccine Institute, Seoul 08826, KoreaGenNBio Inc., Seoul 06026, KoreaResearch Institute, SL VaxiGen Inc., Korea Bio Park, Seongnam 13488, KoreaThe unprecedented and rapid spread of SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) has motivated the need for a rapidly producible and scalable vaccine. Here, we developed a synthetic soluble SARS-CoV-2 spike (S) DNA-based vaccine candidate, GX-19. In mice, immunization with GX-19 elicited not only S-specific systemic and pulmonary antibody responses but also Th1-biased T cell responses in a dose-dependent manner. GX-19-vaccinated nonhuman primates seroconverted rapidly and exhibited a detectable neutralizing antibody response as well as multifunctional CD4+ and CD8+ T cell responses. Notably, when the immunized nonhuman primates were challenged at 10 weeks after the last vaccination with GX-19, they had reduced viral loads in contrast to non-vaccinated primates as a control. These findings indicate that GX-19 vaccination provides a durable protective immune response and also support further development of GX-19 as a vaccine candidate for SARS-CoV-2.https://www.mdpi.com/2076-393X/9/4/307COVID-19DNA vaccine |
| spellingShingle | Yong Bok Seo You Suk Suh Ji In Ryu Hwanhee Jang Hanseul Oh Bon-Sang Koo Sang-Hwan Seo Jung Joo Hong Manki Song Sung-Joo Kim Young Chul Sung Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates Vaccines COVID-19 DNA vaccine |
| title | Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates |
| title_full | Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates |
| title_fullStr | Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates |
| title_full_unstemmed | Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates |
| title_short | Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates |
| title_sort | soluble spike dna vaccine provides long term protective immunity against sars cov 2 in mice and nonhuman primates |
| topic | COVID-19 DNA vaccine |
| url | https://www.mdpi.com/2076-393X/9/4/307 |
| work_keys_str_mv | AT yongbokseo solublespikednavaccineprovideslongtermprotectiveimmunityagainstsarscov2inmiceandnonhumanprimates AT yousuksuh solublespikednavaccineprovideslongtermprotectiveimmunityagainstsarscov2inmiceandnonhumanprimates AT jiinryu solublespikednavaccineprovideslongtermprotectiveimmunityagainstsarscov2inmiceandnonhumanprimates AT hwanheejang solublespikednavaccineprovideslongtermprotectiveimmunityagainstsarscov2inmiceandnonhumanprimates AT hanseuloh solublespikednavaccineprovideslongtermprotectiveimmunityagainstsarscov2inmiceandnonhumanprimates AT bonsangkoo solublespikednavaccineprovideslongtermprotectiveimmunityagainstsarscov2inmiceandnonhumanprimates AT sanghwanseo solublespikednavaccineprovideslongtermprotectiveimmunityagainstsarscov2inmiceandnonhumanprimates AT jungjoohong solublespikednavaccineprovideslongtermprotectiveimmunityagainstsarscov2inmiceandnonhumanprimates AT mankisong solublespikednavaccineprovideslongtermprotectiveimmunityagainstsarscov2inmiceandnonhumanprimates AT sungjookim solublespikednavaccineprovideslongtermprotectiveimmunityagainstsarscov2inmiceandnonhumanprimates AT youngchulsung solublespikednavaccineprovideslongtermprotectiveimmunityagainstsarscov2inmiceandnonhumanprimates |